skip to main content
Show Results with:

Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?

Peng, Meng et al.

Current medical research and opinion. Volume 31:Number 1 (2015, January); pp 177-182 -- Informa Healthcare

Online access

  • Title:
    Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?
  • Author: Peng, Meng;
    Jiang, Xiong-jing;
    Dong, Hui;
    Zou, Yu-bao;
    Zhang, Hui-min;
    Wu, Hai-ying;
    Yang, Yuejin
  • Found In: Current medical research and opinion. Volume 31:Number 1 (2015, January); pp 177-182
  • Journal Title: Current medical research and opinion
  • Subjects: Clinical medicine--Periodicals; Therapeutics--Periodicals; Dewey: 615.5
  • Rights: legaldeposit
  • Publication Details: Informa Healthcare
  • Abstract: Abstract Objective:

    To investigate the renal-protective effect of lercanidipine in patients undergoing renal artery intervention.

    Methods:

    A prospective, single-center, cohort study was conducted and patients, 30–75 years of age, with atherosclerotic renal artery stenosis were consecutively enrolled between September 2011 and October 2012. Lercanidipine (10–20 mg/day) was regularly taken after the intervention. Follow up visits were performed at 3 and 6 months after the intervention. Serum creatinine, clinical blood pressure, 24 hour ambulatory blood pressure, pulse wave velocity, and 24 hour urine protein were assessed. Adverse events were recorded.

    Results:

    In total, 55 patients (mean age 63.5 ± 8.9 years) were enrolled and 52 completed the study. Renal function, estimated glomerular filtration rate (eGFR) and 24 hour urine protein at 3 months after the intervention were not statistically different compared with the baseline. At 6 months after the intervention eGFR significantly increased versus baseline (78 ± 23 ml/min/1.73 m2 vs 71 ± 21 ml/min/1.73 m2, p = 0.021); 24 hour urine protein decreased significantly (0.02 g [IQR, 0.01–0.1] vs 0.03 g [IQR, 0.01–0.28], p = 0.042). Blood pressure control improved at 3 months and 6 months after the intervention. The need for antihypertensive drugs decreased; clinical systolic blood pressure, diastolic blood pressure and 24 hour average systolic blood pressure and diastolic blood pressure decreased. The pulse wave velocity decreased after 3 and 6 months. At the end of follow-up, none of the following adverse events occurred: death, dialysis, myocardial infarction or stroke. Mild lower extremity edema occurred in only one patient. No other side effects occurred.

    Conclusions:

    This study showed that lercanidipine can improve renal function in patients undergoing renal artery intervention.


  • Identifier: ETOClsidyv8f83e13a; System Number: LDEAvdc_100025062870.0x000001; Journal ISSN: 0300-7995; 10.1185/03007995.2014.960071
  • Publication Date: 2015
  • Physical Description: Electronic
  • Shelfmark(s): ELD Digital store

Searching Remote Databases, Please Wait